Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
05/2012
05/03/2012WO2012058241A2 Methods and compositions for ameliorating pancreatic cancer
05/03/2012WO2012057363A1 Adeno-associated virus virions for transferring genes into neural cells
05/03/2012WO2012057294A1 Method for treating malaria, method for killing malaria parasite, and use of the methods
05/03/2012WO2012056457A2 Compositions and methods for activating expression by a specific endogenous mirna
05/03/2012WO2012056449A2 Compositions and methods for specific cleavage of exogenous rna in a cell
05/03/2012WO2012056440A1 COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
05/03/2012WO2012055971A1 Microvesicles derived from atheroprotective endothelial cells for the treatment and prevention of atherosclerotic diseases
05/03/2012WO2012055551A2 Nf-kb signal path-manipulated dendritic cells
05/03/2012WO2012055362A1 Hbv treatment
05/03/2012WO2011150320A3 Activators of innate immunity
05/03/2012US20120110684 Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy
05/03/2012US20120108880 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
05/03/2012US20120108657 Disease-associated protein
05/03/2012US20120108653 Oligomers
05/03/2012US20120108523 Disease-associated protein
05/03/2012US20120107897 Double-stranded oligonucleotides
05/03/2012US20120107827 PSMCs As Modifiers of the RB Pathway and Methods of Use
05/03/2012US20120107390 Feline infectious peritonitis vaccine
05/03/2012US20120107313 Mammalian receptor proteins; related reagents and methods
05/03/2012US20120107303 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
05/03/2012US20120107299 Phosphorylation-inhibiting agent or dephosphorylating agent for pten
05/03/2012US20120107297 Method for therapeutic angiogenesis
05/03/2012US20120107284 Stem cells for transplantation and methods for production thereof
05/03/2012US20120107247 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their Use as Diagnostic Reagents and Vaccines
05/03/2012CA2853613A1 Hbv treatment
05/03/2012CA2824604A1 Compositions and methods for activating expression by a specific endogenous mirna
05/02/2012EP2447370A1 MicroRNA molecules
05/02/2012EP2446929A1 Microvesicles derived from atheroprotective endothelial cells for the treatment and prevention of atherosclerotic diseases
05/02/2012EP2446890A1 High viscosity macromolecular compositions for treating ocular conditions
05/02/2012EP2446037A2 Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
05/02/2012EP2445538A2 Aptamer-targeted sirna to inhibit nonsense mediated decay
05/02/2012EP2124993B1 Composition comprising the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors including the corresponding nucleic sequences and their therapeutic use
05/02/2012EP1993603B1 Hepatitis c virus non structural fusion protein
05/02/2012EP1664315B1 Aav vectors for in vivo gene therapy of rheumatoid arthritis
05/02/2012EP1389130B1 Use of osteopontin for the treatment and/or prevention of neurologic diseases
05/02/2012EP1343822B1 Means for the diagnosis and therapy of ctcl
05/02/2012CN1404398B Improved DNA vaccines for production-type animals
05/02/2012CN102439148A Sirna conjugate and preparation method thereof
05/02/2012CN102439147A Vangl1 peptides and vaccines including the same
05/02/2012CN102439136A Mesenchymal stem cells producing inhibitory rna for disease modification
05/02/2012CN102438658A Non-integrating retroviral vector vaccines
05/02/2012CN102438647A Treatment of eye diseases using encapsulated cells encoding and secreting a neuroprotective factor and/or an anti-angiogenic factor
05/02/2012CN102433383A Applications and correlated medicament of human STIM1 gene
05/02/2012CN102433343A Preparation method of trichina and tumor related protein gene and medical application
05/02/2012CN102433336A Micro-molecular interference ribonucleic acid (RNA) for inhibiting glioma proliferation and promoting glioma apoptosis as well as preparation method and application thereof
05/02/2012CN102430129A Bone morphogenetic protein-2/basic fibroblast growth factor (BMP-2/bFGF) double-gene chitosan nano-microcapsules and application thereof
05/02/2012CN102430128A Application of signal-regulatory protein alpha (SIRPalpha) in preparation of medicines for preventing and treating allergic diseases
05/02/2012CN102429868A Liposome medicinal composition with tumor targeting, in-vivo tracing and treating functions and preparation method thereof
05/02/2012CN101892240B Japanese blood fluke beta-catenin gene, protein and application
05/02/2012CN101760475B Recombinant retroviral vector
05/02/2012CN101671669B Hepatocellular carcinoma targeting gene expression element AE and applications thereof
05/02/2012CN101560245B CTL epitope polypeptide of avian influenza H5N1 virus and application thereof
05/02/2012CN101270160B Monoclone antibody 1F1, uses thereof and hybridoma cell line BCSP31-1F1 excreting the antibody
05/01/2012US8168776 Method for making a 21 nucleotide double stranded RNA chemically linked at one end
05/01/2012US8168775 Compositions and methods for inhibiting expression of transthyretin
05/01/2012US8168610 Bispecific oligonucleotide for the treatment of CNS malignancies
05/01/2012US8168608 Promoter and plasmid system for genetic engineering
05/01/2012US8168601 contacting the specific cells with a fusion protein-double stranded RNA complex for treating cancer, viral diseases; specifically binds to a site on a target cell; drug screening
05/01/2012US8168600 Compositions and methods for topical delivery of oligonucleotides
05/01/2012US8168583 2-fluoronucleosides
05/01/2012US8168418 Expression of HIV polypeptides and production of virus-like particles
05/01/2012US8168205 Streptococcus pneumoniae polypeptides
05/01/2012US8168201 Vaccines
05/01/2012US8168187 Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
05/01/2012US8168180 Methods and compositions for modulating angiogenesis
05/01/2012US8168178 Methods and compositions for regulating lymphocyte activity
05/01/2012US8168169 Methods and compositions for the treatment of medical disorders
05/01/2012US8168168 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
05/01/2012US8168166 Live genetically attenuated malaria vaccine
05/01/2012CA2491040C Thrombin-cleavable factor x analogues
04/2012
04/26/2012WO2012054747A2 Methods and compositions for treating tumors using myeloid derived suppressor cells
04/26/2012WO2012054723A2 Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
04/26/2012WO2012054365A2 Novel low molecular weight cationic lipids for oligonucleotide delivery
04/26/2012WO2012053741A2 Nucleic acid molecules inducing rna interference, and uses thereof
04/26/2012WO2012053622A1 Non-human animal, cell, method for evaluation of blood pressure regulator, method for evaluation of condition for regulation of blood pressure, and method for regulation of blood pressure
04/26/2012WO2012052872A2 Methods and compositions for the treatment of insulin-associated medical conditions
04/26/2012WO2012052594A2 USE OF Dlk1 AS AN ANGIOGENESIS INHIBITOR
04/26/2012WO2012051926A1 Compound molecule, preparation method and pharmaceutical compositions thereof
04/26/2012WO2012028762A3 Cell lines and the use thereof for identifying drugs for thyroid carcinoma
04/26/2012WO2012021165A9 Methods and compositions for treating disorders associated with hyperactive immune system
04/26/2012WO2012014073A3 Vaccines against pregnancy-associated malaria
04/26/2012WO2012012467A3 Modulation of nuclear-retained rna
04/26/2012WO2012012461A3 Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
04/26/2012WO2012009347A3 Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
04/26/2012WO2011159960A3 Reprogramming cancer cells
04/26/2012WO2011118994A3 Nlk as a marker for diagnosis of liver cancer and as a therapeutic agent thereof
04/26/2012WO2009046464A8 Articular cartilage gene therapy with recombinant vector encoding bmp-7
04/26/2012US20120101149 Betulinic Acid Derivatives and Methods of Use Thereof
04/26/2012US20120100077 Mixture of amphipathic molecules and method for modifying cell membranes by means of fusion
04/26/2012DE10009143B4 Nachweis von Humanen Papillomviren Detection of human papillomavirus
04/26/2012CA2818662A1 Nucleic acid molecule inducing rna interference, and uses thereof
04/26/2012CA2815212A1 Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
04/26/2012CA2813024A1 Novel low molecular weight cationic lipids for oligonucleotide delivery
04/25/2012EP2444498A1 Gene therapy for treatment of cancer and hyperproliferative diseases
04/25/2012EP2444482A1 Modulation of SGLT2 expression
04/25/2012EP2444065A1 Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
04/25/2012EP2443238A2 Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
04/25/2012EP2443237A2 Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
04/25/2012EP2146727B1 High viscosity macromolecular compositions for treating ocular conditions
04/25/2012EP1601767B1 USE OF siRNA TO SUPPRESS EXPRESSION OF EIF-5A1 IN THE TREATMENT OF GLAUCOMA
1 ... 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 ... 870